{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:14:04Z","timestamp":1791231244631,"version":"4.1.0"},"publisher-location":"Chichester, UK","reference-count":115,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd007287.pub2","type":"reference-entry","created":{"date-parts":[[2010,1,18]],"date-time":"2010-01-18T19:55:28Z","timestamp":1263844528000},"source":"Crossref","is-referenced-by-count":9,"title":["Antigen-specific active immunotherapy for ovarian cancer"],"prefix":"10.1002","author":[{"given":"Ninke","family":"Leffers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toos","family":"Daemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wijnand","family":"Helfrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H Marike","family":"Boezen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J","family":"Cohlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kees","family":"Melief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans W","family":"Nijman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,20]]},"reference":[{"key":"10.1002\/14651858.CD007287.pub2-BIB1|cit1","series-title":"American Society of Clinical Oncology Annual Meeting","article-title":"Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer","author":"Berek","year":"2001"},{"issue":"17","key":"10.1002\/14651858.CD007287.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.2004.09.016","article-title":"Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer","volume":"22","author":"Berek","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD007287.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/CJI.0b013e31816060ce","article-title":"CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer","volume":"31","author":"Berek","year":"2008","journal-title":"Journal of Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","article-title":"Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer","volume":"27","author":"Berek","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007287.pub2-BIB5|cit5","series-title":"2008 ASCO Annual Meeting Proceedings","article-title":"Evaluation of maintenance mono-immunotherapy to improve outcomes in advanced ovarian cancer (OV CA)","author":"Berek","year":"2008"},{"key":"10.1002\/14651858.CD007287.pub2-BIB6|cit6","series-title":"American Society of Clinical Oncology Annual Meeting","article-title":"Prospective evaluation of front-line chemo-immunotherapy (C-IT) with oregovomab (2 alternative dosing schedules) carboplatin-paclitaxel (C-P) in advanced ovarian cancer (OC)","author":"Braly","year":"2007"},{"key":"10.1002\/14651858.CD007287.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CJI.0b013e31818b3dad","article-title":"The immune adjuvant properties of front-line carboplatin-paclitaxel: a randomised phase 2 study of alternative schedules of intravenouw oregovomab chemoimmunotherapy in advanced ovarian cancer","volume":"32","author":"Braly","year":"2009","journal-title":"Journal of Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub2-BIB8|cit8","series-title":"Society of Gynecologic Oncologists Annual Meeting on Women's Cancer","article-title":"Oregovomab immune-modulating antibody therapy concurrent tot standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience","author":"Method","year":"2006"},{"issue":"9","key":"10.1002\/14651858.CD007287.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1182\/blood.V96.9.3102","article-title":"Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells","volume":"96","author":"Brossart","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD007287.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CJI.0b013e31816dad10","article-title":"A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer","volume":"31","author":"Chianese-Bullock","year":"2008","journal-title":"Journal of Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub2-BIB11|cit11","series-title":"Society of Gynecologic Oncologists: Annual Meeting on Women's Cancer","article-title":"Autologous dendritic cell (IDD-6) vaccination as consolidation for advanced ovarian cancer","author":"Chu","year":"2008"},{"issue":"9","key":"10.1002\/14651858.CD007287.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-07-4619","article-title":"Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission","volume":"14","author":"Diefenbach","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1002\/14651858.CD007287.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1525-1438.2005.00483.x","article-title":"A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer","volume":"15","author":"Ehlen","year":"2005","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD007287.pub2-BIB14|cit14","series-title":"American Society of Clinical Oncology Annual Meeting","article-title":"Therapeutic anti-cancer vaccine: a randomized double blind dose comparison study of sialyl Tn-KLH with Detox-B SE adjuvant for active specific immunotherapy of ovarian cancer (OC)","author":"Freedman","year":"1998"},{"key":"10.1002\/14651858.CD007287.pub2-BIB15|cit15","series-title":"American Society of Clinical Oncology Annual Meeting","article-title":"Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN-K with detox-B SE adjuvant for active specific immunotherapy of ovarian cancer (OC)","author":"Termrungruanglert","year":"1996"},{"issue":"2","key":"10.1002\/14651858.CD007287.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ygyno.2004.04.024","article-title":"CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients","volume":"94","author":"Gordon","year":"2004","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD007287.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1158\/1078-0432.CCR-08-0126","article-title":"Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma","volume":"14","author":"Gulley","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD007287.pub2-BIB18|cit18","series-title":"American Society of Clinical Oncology Annual Meeting","article-title":"A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide-pulsed dendritic cells in high risk ovarian cancer patients","author":"Herrin","year":"2007"},{"key":"10.1002\/14651858.CD007287.pub2-BIB19|cit19","series-title":"American Society of Clinical Oncology Annual Meeting","article-title":"Wild-type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom","author":"Herrin","year":"2003"},{"key":"10.1002\/14651858.CD007287.pub2-BIB20|cit20","article-title":"Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial","author":"Leffers","journal-title":"International Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1349-7006.2002.tb01203.x","article-title":"Functional mimicry of an anti-idiotypic antibody to nominal antigen on cellular response","volume":"93","author":"Ma","year":"2002","journal-title":"Japanese Journal of Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD007287.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00002371-199205000-00008","article-title":"Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen","volume":"11","author":"MacLean","year":"1992","journal-title":"Journal of Immunotherapy"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00002371-199601000-00007","article-title":"Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine","volume":"19","author":"MacLean","year":"1996","journal-title":"Journal of Immunotherapy With Emphasis on Tumor Immunology"},{"key":"10.1002\/14651858.CD007287.pub2-BIB24|cit24","series-title":"American Society of Clinical Oncology Annual Meeting","article-title":"Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC)","author":"Method","year":"2002"},{"key":"10.1002\/14651858.CD007287.pub2-BIB25|cit25","series-title":"American Association of Cancer Research Annual Meeting","article-title":"Clinical outcomes following immunotherapy with a MUC1\/CEA vaccine in patients with metastatic breast and ovarian cancer","author":"Mohebtash","year":"2009"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1067\/mob.2003.347","article-title":"Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer","volume":"189","author":"Mobus","year":"2003","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"9","key":"10.1002\/14651858.CD007287.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00262-004-0522-z","article-title":"A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer","volume":"53","author":"Nicholson","year":"2004","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"10","key":"10.1002\/14651858.CD007287.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.4049\/jimmunol.176.10.6340","article-title":"Influence of CD4(+)CD25(+) regulatory T cells on low\/high-avidity CD4(+) T cells following peptide vaccination","volume":"176","author":"Nishikawa","year":"2006","journal-title":"Journal of Immunology"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/10849780152389384","article-title":"Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo","volume":"16","author":"Noujaim","year":"2001","journal-title":"Cancer Biotherapy & Radiopharmaceuticals"},{"issue":"31","key":"10.1002\/14651858.CD007287.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"12837","DOI":"10.1073\/pnas.0703342104","article-title":"Vaccination with an NY-ESO-1 peptide of HLA class I\/II specificities induces integrated humoral and T cell responses in ovarian cancer","volume":"104","author":"Odunsi","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD007287.pub2-BIB31|cit31","series-title":"Society of Gynecologic Oncologists Annual Meeting on Women's Cancer","article-title":"Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY-ESO-1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer","author":"Odunsi","year":"2007"},{"issue":"10","key":"10.1002\/14651858.CD007287.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/annonc\/mdl357","article-title":"The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR","volume":"17","author":"Pfisterer","year":"2006","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/1078-0432.CCR-03-0056","article-title":"Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib\/II)","volume":"10","author":"Reinartz","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub2-BIB34|cit34","first-page":"1154","article-title":"Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment","volume":"7","author":"Wagner","year":"2001","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub2-BIB35|cit35","first-page":"79","article-title":"Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial","volume":"87","author":"Sabbatini","year":"2000","journal-title":"Clinical Cancer Research"},{"issue":"18","key":"10.1002\/14651858.CD007287.pub2-BIB36|cit36","first-page":"5503","article-title":"Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer","volume":"12","author":"Sabbatini","year":"2006","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD007287.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1158\/1078-0432.CCR-06-2949","article-title":"Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer","volume":"13","author":"Sabbatini","year":"2007","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00002371-199901000-00008","article-title":"Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine","volume":"22","author":"Sandmaier","year":"1999","journal-title":"Journal of Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub2-BIB39|cit39","series-title":"American Society of Clinical Oncology Annual Meeting","article-title":"Anti-idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex-Mab-B43.13","author":"Schultes","year":"1999"},{"issue":"4","key":"10.1002\/14651858.CD007287.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002620050479","article-title":"Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)","volume":"46","author":"Schultes","year":"1998","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1756-9966-28-18","article-title":"Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis","volume":"28","author":"Str\u00f6hlein","year":"2009","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00002371-200401000-00006","article-title":"Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers","volume":"27","author":"Tsuda","year":"2004","journal-title":"Journal of Immunotherapy"},{"issue":"9","key":"10.1002\/14651858.CD007287.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00432-002-0348-z","article-title":"Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study","volume":"128","author":"Zanten-Przybysz","year":"2002","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub2-BIB45|cit44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1089\/hyb.1993.12.521","article-title":"Antitumor antibodies for immunotherapy of ovarian carcinomas","volume":"12","author":"Wagner","year":"1993","journal-title":"Hybridoma"},{"key":"10.1002\/14651858.CD007287.pub2-BIB44|cit45","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF02789234","article-title":"Monoclonal antibodies and idiotypic network activation for ovarian carcinoma","volume":"24-25","author":"Wagner","year":"1994","journal-title":"Cell Biophysics"},{"issue":"9","key":"10.1002\/14651858.CD007287.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s002620000143","article-title":"Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides","volume":"49","author":"Anderson","year":"2000","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub2-BIB47|cit47","first-page":"16","article-title":"LUD 00-009: Phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer","volume":"7","author":"Bender","year":"2007","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"22","key":"10.1002\/14651858.CD007287.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.2005.03.158","article-title":"Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome","volume":"23","author":"Carbone","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007287.pub2-BIB49|cit49","first-page":"1289","article-title":"Generation of immunity to the HER-2\/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine","volume":"5","author":"Disis","year":"1999","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD007287.pub2-BIB50|cit50","first-page":"1347","article-title":"Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2\/neu peptide immunization","volume":"6","author":"Disis","year":"2000","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10.1002\/14651858.CD007287.pub2-BIB51|cit51","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1200\/JCO.2002.06.171","article-title":"Generation of T-cell immunity to the HER-2\/neu protein after active immunization with HER-2\/neu peptide-based vaccines","volume":"20","author":"Disis","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD007287.pub2-BIB52|cit52","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1182\/blood.V99.8.2845","article-title":"Flt3 ligand as a vaccine adjuvant in association with HER-2\/neu peptide-based vaccines in patients with HER-2\/neu-overexpressing cancers","volume":"99","author":"Disis","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub2-BIB53|cit53","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1023\/B:JOCI.0000040928.67495.52","article-title":"Humoral epitope-spreading following immunization with a HER-2\/neu peptide based vaccine in cancer patients","volume":"24","author":"Disis","year":"2004","journal-title":"Journal of Clinical Immunology"},{"issue":"10","key":"10.1002\/14651858.CD007287.pub2-BIB54|cit54","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2004.09.005","article-title":"Effect of dose on immune response in patients vaccinated with an her-2\/neu intracellular domain protein--based vaccine","volume":"22","author":"Disis","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub2-BIB55|cit55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00262-001-0255-1","article-title":"Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial","volume":"51","author":"Hernando","year":"2002","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub2-BIB56|cit56","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(07)70142-0","article-title":"Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-(alpha) for relapsed metastatic ovarian cancer","volume":"8","author":"Hernando","year":"2007","journal-title":"Lancet Oncology"},{"issue":"12","key":"10.1002\/14651858.CD007287.pub2-BIB57|cit57","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/sj.bmt.1702430","article-title":"Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine","volume":"25","author":"Holmberg","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1002\/14651858.CD007287.pub2-BIB58|cit58","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/sj.gt.3300455","article-title":"Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes","volume":"4","author":"Hui","year":"1997","journal-title":"Gene Therapy"},{"issue":"39","key":"10.1002\/14651858.CD007287.pub2-BIB59|cit59","doi-asserted-by":"crossref","first-page":"14453","DOI":"10.1073\/pnas.0606512103","article-title":"Recombinant vaccinia\/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients","volume":"103","author":"Jager","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1002\/14651858.CD007287.pub2-BIB60|cit60","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1172\/JCI11752","article-title":"Immunization with a HER-2\/neu helper peptide vaccine generates HER-2\/neu CD8 T-cell immunity in cancer patients","volume":"107","author":"Knutson","year":"2001","journal-title":"Journal of Clinical Investigation"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub2-BIB61|cit61","first-page":"1014","article-title":"Immunization of cancer patients with a HER-2\/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity","volume":"8","author":"Knutson","year":"2002","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD007287.pub2-BIB62|cit62","series-title":"Journal of Immunotherapy","first-page":"943","article-title":"Different quality of T cell repsonses to WT1 peptide vaccination in patients with AML\/MDS and patients with solid tumors","author":"Letsch","year":"2008"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD007287.pub2-BIB63|cit63","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/1078-0432.CCR-05-1574","article-title":"Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma","volume":"12","author":"Loveland","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD007287.pub2-BIB64|cit64","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1200\/JCO.2005.10.206","article-title":"Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas","volume":"23","author":"Marshall","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub2-BIB65|cit65","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/(SICI)1097-0215(19990219)84:1<62::AID-IJC12>3.0.CO;2-T","article-title":"Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC\/TR in ovarian-carcinoma patients is associated with longer survival","volume":"84","author":"Miotti","year":"1999","journal-title":"International Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD007287.pub2-BIB66|cit66","first-page":"1331","article-title":"A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen","volume":"5","author":"Morse","year":"1999","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD007287.pub2-BIB67|cit67","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.3816\/CBC.2003.s.007","article-title":"Her2 dendritic cell vaccines","volume":"3 suppl. 4","author":"Morse","year":"2003","journal-title":"Clinical Breast Cancer"},{"issue":"11","key":"10.1002\/14651858.CD007287.pub2-BIB68|cit68","first-page":"3407","article-title":"Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer","volume":"8","author":"Murray","year":"2002","journal-title":"Clinical Cancer Research"},{"issue":"14","key":"10.1002\/14651858.CD007287.pub2-BIB69|cit69","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1158\/1078-0432.CCR-04-0325","article-title":"Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase","volume":"10","author":"Parkhurst","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub2-BIB70|cit70","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s002620050287","article-title":"Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy","volume":"42","author":"Reddish","year":"1996","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1002\/14651858.CD007287.pub2-BIB71|cit71","series-title":"ASCO Annual Meeting","article-title":"A phase I vaccine trial of a HER-2\/neu peptide incorporated into PLG microspheres in patients with advanced stage HER2-expressing cancers","author":"Salazar","year":"2006"},{"issue":"1","key":"10.1002\/14651858.CD007287.pub2-BIB72|cit72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1023\/A:1016009317796","article-title":"Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients","volume":"74","author":"Schiffman","year":"2002","journal-title":"Breast Cancer Research and Treatment"},{"issue":"4","key":"10.1002\/14651858.CD007287.pub2-BIB73|cit73","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/ijc.2910610407","article-title":"CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy","volume":"61","author":"Yacyshyn","year":"1995","journal-title":"International Journal of Cancer"},{"issue":"21","key":"10.1002\/14651858.CD007287.pub2-BIB74|cit74","first-page":"4902","article-title":"Immunization with a peptide epitope (p369-377) from HER-2\/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2\/neu+ tumors","volume":"58","author":"Zaks","year":"1998","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD007287.pub2-BIB75|cit75","unstructured":"University of Alabama at Birmingham and National Cancer Institute (NCI) Phase IB trial of active specific immunotherapy with MVF-HER-2(628-647) and CRL1005 copolymer adjuvant in patients with wetastatic cancer clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB76|cit76","unstructured":"National Cancer Institute (NCI) Vaccine therapy with tumor specific mutated p53 or ras peptides alone or in combination with cellular immunotherapy with peptide activated lymphocytes (PAL cells) along with subcutaneous IL-2 clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB77|cit77","unstructured":"National Cancer Institute (NCI) Vaccine therapy with tumor specific p53 peptides in adult patients with adenocarcinoma of the breast or ovary clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB78|cit78","unstructured":"Southwest Oncology Group and National Cancer Institute (NCI) An early phase study of an EGFRvIII peptide based vaccine in patients with EGFRvIII expressing cancers clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB79|cit79","unstructured":"Unither Pharmaceuticals A comparative pharmacokinetics and safety study of OvaRex MAb-B43.13 in patients with ovarian epithelial carcinoma clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB80|cit80","unstructured":"Unither Pharmaceuticals Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma clinicatrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB81|cit81","unstructured":"National Cancer Institute (NCI) An open label pilot study to evaluate the safety and tolerability of PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in combination with sargramostim in adults with metastatic carcinoma clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB82|cit82","unstructured":"University of Virginia Cancer Center and National Cancer Institute (NCI) Evaluation of the immunogenicity of vaccination with synthetic peptides in adjuvant in patients with advanced ovarian, primary peritoneal, or fallopian tube cancer clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB83|cit83","unstructured":"Eisai Medical Research Inc A phase 1 open-label study of the safety and feasibility of ZYC300 administration with cyclophosphamide pre-dosing clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB84|cit84","unstructured":"Menarini Group Efficacy multicentre trial of immunotherapy vaccination with abagovomab to treat ovarian cancer patients (MIMOSA) clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB85|cit85","unstructured":"Duke University A phase I study of ovarian cancer peptides plus GM-CSF and adjuvant (Montanide ISA-51) as consolidation following optimal debulking and systemic chemotherapy for women with advanced stage ovarian, tubal, or peritoneal cancer clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB86|cit86","unstructured":"Anza Therapeutics Inc Study of safety and tolerability of intravenous CRS-207 in adults with selected advanced solid tumors who have failed or who are not candidates for standard treatment clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB87|cit87","unstructured":"Ludwig Institute for Cancer Research and Memorial Sloan-Kettering Cancer Center A phase I study of NY-ESO-1 overlapping peptides (OLP4) with or without immunoadjuvants montanide and poly-ICLC vaccination of epithelial ovarian cancer (EOC), fallopian tube, or primary peritoneal cancer patients in second or third remission clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB88|cit88","unstructured":"National Institute of Health and Celldex Therapeutics A Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted hCG-? Vaccine, in Patients With Incurable Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder and Ovarian Cancer Clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB89|cit89","unstructured":"Gynecologic Oncology Group and National Cancer Institute (NCI) A randomized phase III trial in Patients with epithelial ovarian, fallopian tube or peritoneal cancer with a polyvalent vaccine-KLH conjugate + OPT-821 versus OPT-821 clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB90|cit90","unstructured":"Celldex Therapeutics A phase I, open-label, dose-escalation, multidose study of CDX-1307, a mannose receptor-targeted hCG-\u03b2 vaccine, in patients with incurable breast, colorectal, pancreatic, ovarian or bladder cancer (CDX-1307-01) clinicatrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB91|cit91","unstructured":"Roswell Park Cancer Institute and National Cancer Institute (NCI) Phase I study of ALVAC(2)-NY-ESO-1(M)\/TRICOM in patients with epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumors express NY-ESO-1 or LAGE-1 antigen clinicaltrilas.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB92|cit92","unstructured":"University Medical Centre Groningen p53 synthetic long peptides vaccine with cyclophosphamide for ovarian cancer a phase II trial clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB93|cit93","unstructured":"Gynecologic Oncology Group and National Cancer Institute (NCI) A phase III randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933) + OPT-821 Versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB94|cit94","unstructured":"National Cancer Institute (NCI) Open label phase I study to evaluate the safety and tolerability of vaccine (GI-6207) consisting of whole, heat-killed recombinant saccharomyces cerevisiae genetically modified to express CEA protein in adults with metastatic CEA-expressing carcinoma clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007287.pub2-BIB95|cit95","unstructured":"Roswell Park Cancer Institute and National Cancer Institute (NCI) A phase I clinical trial of NY-ESO-1 protein immunization in combination with 5-AZA-2'-deoxycytidine (decitabine) in patients receiving liposomal doxorubicin for recurrent epithelial ovarian or primary peritoneal carcinoma clinicaltrials.gov"},{"issue":"8","key":"10.1002\/14651858.CD007287.pub2-BIB96|cit96","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ejso.2006.03.041","article-title":"Novel therapeutic agents in ovarian cancer","volume":"32","author":"Agarwal","year":"2006","journal-title":"European Journal of Surgical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub2-BIB97|cit97","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/1078-0432.CCR-05-2013","article-title":"Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer","volume":"12","author":"Antonia","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD007287.pub2-BIB98|cit98","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","article-title":"FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology","volume":"70","author":"Benedet","year":"2000","journal-title":"International Journal of Gynaecology and Obstetrics"},{"key":"10.1002\/14651858.CD007287.pub2-BIB99|cit99","unstructured":"Brighton Collaboration www.brightoncollaboration.org"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub2-BIB100|cit100","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00262-007-0378-0","article-title":"The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays","volume":"57","author":"Britten","year":"2008","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"27","key":"10.1002\/14651858.CD007287.pub2-BIB101|cit101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7270","article-title":"Evaluating non-randomised intervention studies","volume":"7","author":"Deeks","year":"2003","journal-title":"Health Technology Assessment"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub2-BIB102|cit102","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1309\/15B66DQMFYYM78CJ","article-title":"NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma","volume":"125","author":"Dong","year":"2006","journal-title":"American Journal of Clinical Pathology"},{"issue":"11","key":"10.1002\/14651858.CD007287.pub2-BIB103|cit103","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1158\/1078-0432.CCR-07-4025","article-title":"Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement","volume":"14","author":"Garnett","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD007287.pub2-BIB104|cit104","doi-asserted-by":"crossref","first-page":"1455-63","DOI":"10.1158\/1078-0432.CCR-07-0371","article-title":"Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation","volume":"14","author":"Laheru","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD007287.pub2-BIB105|cit105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2217\/1750743X.1.2.163","article-title":"Multimodality treatment warranted for ovarian cancer: immunotherapy, a prerequisite to improve prognosis for this vicious disease","volume":"1","author":"Leffers","year":"2009","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1002\/14651858.CD007287.pub2-BIB106|cit106","first-page":"74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"4","key":"10.1002\/14651858.CD007287.pub2-BIB107|cit107","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/annonc\/mdi112","article-title":"Tumour-infiltrating gamma\/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma","volume":"16","author":"Raspollini","year":"2005","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD007287.pub2-BIB108|cit108","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"Journal of the National Cancer Institute"},{"issue":"51","key":"10.1002\/14651858.CD007287.pub2-BIB109|cit109","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favourable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub2-BIB110|cit110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"issue":"3 Suppl 7","key":"10.1002\/14651858.CD007287.pub2-BIB111|cit111","first-page":"11","article-title":"Chemotherapy for advanced ovarian cancer: overview of randomized trials","volume":"27","author":"Thigpen","year":"2000","journal-title":"Seminars in Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub2-BIB112|cit112","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Seminars in Radiation Oncology"},{"issue":"12","key":"10.1002\/14651858.CD007287.pub2-BIB113|cit113","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0895-4356(98)00131-0","article-title":"The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus","volume":"51","author":"Verhagen","year":"1998","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD007287.pub2-BIB114|cit114","volume-title":"Handbook for Reporting Results of Cancer Treatment","year":"1979"},{"issue":"3","key":"10.1002\/14651858.CD007287.pub2-BIB115|cit115","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"New England Journal of Medicine"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007287.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T00:00:00Z","timestamp":1410912000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD007287.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:08:51Z","timestamp":1628546931000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007287.pub2"}},"subtitle":[],"editor":[{"given":"Ninke","family":"Leffers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,1,20]]},"references-count":115,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007287.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD007287.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2010,1,20]]}}}